Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 16/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22210773 | 1.00 | ALDH1A1 (0.54) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL30011128 | 1.00 | ALDH1A1 (0.54) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL2933766 | 0.96 | ALDH1A1 (0.58) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL31025662 | 0.96 | ALDH1A1 (0.58) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL2933768 | 0.96 | ALDH1A1 (0.58) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL7441174 | 0.96 | ALDH1A1 (0.58) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL31139337 | 0.95 | ALDH1A1 (0.50) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL31139305 | 0.95 | ALDH1A1 (0.50) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL30592760 | 0.95 | ALDH1A1 (0.50) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL4982161 | 0.93 | ALDH1A1 (0.51) | ALDH1A1ENPEPL3MBTL1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287509-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2024-08-29 | — | — | US | claimed |
| EP-4056168-A9 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-11-23 | — | — | EP | claimed |
| EP-4056168-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-09-14 | — | — | EP | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-12371691-B2 | Nano complex for targeted repairing of neurovascular lesion, and preparation and use thereof | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2025-07-29 | — | — | US | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-20240300999-A1 | PEPTIDES FOR REGULATING GLUCOSE | GILL THOMAS A (CA) | 2024-09-12 | — | — | US | disclosed |
| US-20240287509-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2024-08-29 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-4056168-A9 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-11-23 | — | — | EP | disclosed |
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | CUREVAC AG (DE) | 2022-10-25 | — | — | US | disclosed |
| EP-4056168-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-09-14 | — | — | EP | disclosed |
| CN-114605496-A | Polypeptide and application thereof, antibacterial drug and preparation method thereof | 华中科技大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-3206704-B1 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES | RIPTIDE BIOSCIENCE INC (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | HNRNPH1, HNRNPH3, SNRPE | ALDH1A1 4759/4885ENPEP 1575/4885L3MBTL1 369/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ALDH1A1 3596/4885ENPEP 18/4885L3MBTL1 184/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | ALDH1A1 4283/4885ENPEP 910/4885L3MBTL1 422/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ALDH1A1 4110/4885ENPEP 5/4885L3MBTL1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.